AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine

 

A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazine is more effective than the opioid drug, hydromorphone. The randomized, double-blind, comparative study was conducted in two emergency departments (EDs) in New York City. Qualifying patients visiting the ED for acute migraine treatment were assigned to receive prochlorperazine 10 mg plus diphenhydramine 25 mg, or hydromorphone 1 mg. Results showed that sustained headache relief was achieved by significantly more patients in the prochlorperazine group (60 percent) compared to the hydromorphone group (31 percent). The trial was halted early because the results were clear and continued administration of the less-effective treatment, hydromorphone, would raise ethical issues.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC